Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GPR132 | Q9UNW8 | 6/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.48 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753264 | 0.86 | LTA4H (0.57) | MAPK1SMN1; SMN2HTR1ADRD2 | |
| SCHEMBL13097042 | 0.85 | LTA4H (0.61) | MAPK1MAOBCYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL28011530 | 0.85 | MAPK1 (0.64) | MAPK1GRM2MAOBLMNAGPR132 | |
| SCHEMBL13097025 | 0.84 | DRD2 (0.49) | MAPK1CYP4F2CYP4A11GPR132HTR1A | |
| SCHEMBL13106257 | 0.83 | TDP1 (0.58) | MAPK1GRM2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL13097026 | 0.82 | MAPT (0.48) | MAPK1GRM2MAOBALDH1A1LMNA | |
| SCHEMBL12015516 | 0.81 | F2 (0.51) | MAPK1ALDH1A1LMNASMN1; SMN2DRD2 | |
| SCHEMBL28048769 | 0.80 | CYP11B1 (0.57) | — | |
| SCHEMBL1323646 | 0.80 | RAB9A (0.62) | MAPK1GRM2ALDH1A1HTR1ADRD2 | |
| SCHEMBL30150593 | 0.80 | RAB9A (0.62) | MAPK1GRM2ALDH1A1HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | MAPK1 1589/4885GRM2 3040/4885MAOB 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.